A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Jan 4

PMID 33391285

Citations 28

Authors

Anna C Fagre

John Manhard

Rachel Adams

Miles Eckley

Shijun Zhan

Juliette Lewis

Savannah M Rocha

Catherine Woods

Karina Kuo

Wuxiang Liao

Lin Li

Adam Corper

Dilip Challa

Emily Mount

Christine Tumanut

Ronald B Tjalkens

Tawfik Aboellail

Xiaomin Fan

Tony Schountz

Affiliations

Soon will be listed here.

Abstract

The emergence of COVID-19 has led to a pandemic that has caused millions of cases of disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir and dexamethasone have demonstrated limited efficacy, only slightly reducing disease burden, thus novel approaches for clinical management of COVID-19 are needed. We identified a panel of human monoclonal antibody clones from a yeast display library with specificity to the SARS-CoV-2 spike protein receptor binding domain that neutralized the virus . Administration of the lead antibody clone to Syrian hamsters challenged with SARS-CoV-2 significantly reduced viral load and histopathology score in the lungs. Moreover, the antibody interrupted monocyte infiltration into the lungs, which may have contributed to the reduction of disease severity by limiting immunopathological exacerbation. The use of this antibody could provide an important therapy for treatment of COVID-19 patients.

Citing Articles

In vitro antibody-mediated SARS-CoV-2 infection suppression through human ACE2 receptor blockade.

Redd P, Merting A, Klement J, Poschel D, Yang D, Liu K Immunol Lett. 2024; 268:106887.

PMID: 38925442 PMC: 11256821. DOI: 10.1016/j.imlet.2024.106887.

A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection.

Adams L, VanBlargan L, Liu Z, Gilchuk P, Zhao H, Chen R Cell Rep Med. 2023; 4(12):101305.

PMID: 38039973 PMC: 10772349. DOI: 10.1016/j.xcrm.2023.101305.

Immunoglobulin Y Specific for SARS-CoV-2 Spike Protein Subunits Effectively Neutralizes SARS-CoV-2 Infectivity and Ameliorates Disease Manifestations In Vivo.

Yeh C, Lee C, Ho Y, Chen S, Chen L, Liu P Biomedicines. 2022; 10(11).

PMID: 36359294 PMC: 9687769. DOI: 10.3390/biomedicines10112774.

Characteristics of animal models for COVID-19.

Qi F, Qin C Animal Model Exp Med. 2022; 5(5):401-409.

PMID: 36301011 PMC: 9610135. DOI: 10.1002/ame2.12278.

Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model.

Imbrechts M, Maes W, Ampofo L, Van den Berghe N, Calcoen B, Van Looveren D iScience. 2022; 25(8):104705.

PMID: 35813873 PMC: 9250818. DOI: 10.1016/j.isci.2022.104705.

References

Wang C, Li W, Drabek D, Okba N, van Haperen R, Osterhaus A . A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020; 11(1):2251. PMC: 7198537. DOI: 10.1038/s41467-020-16256-y. View

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

Erol A . Role of oxidized LDL-induced "trained macrophages" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis. Diabetes Metab Syndr. 2020; 14(4):713-714. PMC: 7214326. DOI: 10.1016/j.dsx.2020.05.007. View

Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H . Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020; 581(7807):221-224. PMC: 7328981. DOI: 10.1038/s41586-020-2179-y. View

Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X . Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A. 2007; 104(29):12123-8. PMC: 1924550. DOI: 10.1073/pnas.0701000104. View

Cao X . COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020; 20(5):269-270. PMC: 7143200. DOI: 10.1038/s41577-020-0308-3. View

Berry J, Jones S, Drebot M, Andonov A, Sabara M, Yuan X . Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J Virol Methods. 2004; 120(1):87-96. PMC: 7119589. DOI: 10.1016/j.jviromet.2004.04.009. View

Ichiyama T, Yoshitomi T, Nishikawa M, Fujiwara M, Matsubara T, Hayashi T . NF-kappaB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol. 2001; 99(3):373-7. DOI: 10.1006/clim.2001.5026. View

Wilson N, Kvalsvig A, Telfar Barnard L, Baker M . Case-Fatality Risk Estimates for COVID-19 Calculated by Using a Lag Time for Fatality. Emerg Infect Dis. 2020; 26(6):1339-1441. PMC: 7258483. DOI: 10.3201/eid2606.200320. View

10.

Netea M, Joosten L, Latz E, Mills K, Natoli G, Stunnenberg H . Trained immunity: A program of innate immune memory in health and disease. Science. 2016; 352(6284):aaf1098. PMC: 5087274. DOI: 10.1126/science.aaf1098. View

11.

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z . Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMC: 7048180. DOI: 10.1080/22221751.2020.1729069. View

12.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

13.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

14.

Ter Meulen J, Bakker A, van den Brink E, Weverling G, Martina B, Haagmans B . Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet. 2004; 363(9427):2139-41. PMC: 7112500. DOI: 10.1016/S0140-6736(04)16506-9. View

15.

Pagliaro P . Is macrophages heterogeneity important in determining COVID-19 lethality?. Med Hypotheses. 2020; 143:110073. PMC: 7332450. DOI: 10.1016/j.mehy.2020.110073. View

16.

Imai Y, Kuba K, Neely G, Yaghubian-Malhami R, Perkmann T, van Loo G . Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008; 133(2):235-49. PMC: 7112336. DOI: 10.1016/j.cell.2008.02.043. View

17.

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020; 586(7830):578-582. PMC: 8436420. DOI: 10.1038/s41586-020-2608-y. View

18.

Shi R, Shan C, Duan X, Chen Z, Liu P, Song J . A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020; 584(7819):120-124. DOI: 10.1038/s41586-020-2381-y. View

19.

Wang L, Shi W, Chappell J, Joyce M, Zhang Y, Kanekiyo M . Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. J Virol. 2018; 92(10). PMC: 5923077. DOI: 10.1128/JVI.02002-17. View

20.

Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K . Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol. 1988; 48(2):247-51. DOI: 10.1016/0090-1229(88)90088-8. View